Sugi Predict

Sugi Predict / Targets / MAP2K3

MAP2K3

Dual specificity mitogen-activated protein kinase kinase 3 · P46734 · MAP2K3 on Sugi Atlas →

4,417 patent compounds predicted against MAP2K3, 3,112 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL1463744 SCHEMBL1463744 0.71 3/20
SCHEMBL1792072 SCHEMBL1792072 0.71 3/20
SCHEMBL2466331 SCHEMBL2466331 0.51 3/20
SCHEMBL3644935 SCHEMBL3644935 0.57 2/20
SCHEMBL561316 SCHEMBL561316 0.54 2/20
SCHEMBL3470054 SCHEMBL3470054 0.54 2/20
SCHEMBL668419 SCHEMBL668419 0.53 2/20
SCHEMBL2662338 SCHEMBL2662338 0.51 2/20
SCHEMBL3461304 SCHEMBL3461304 0.51 2/20
SCHEMBL1332157 SCHEMBL1332157 0.50 2/20
SCHEMBL1641573 SCHEMBL1641573 0.50 2/20
SCHEMBL3088513 SCHEMBL3088513 0.50 2/20
SCHEMBL1034290 SCHEMBL1034290 0.46 2/20
SCHEMBL43146 SCHEMBL43146 0.46 2/20
SCHEMBL699068 SCHEMBL699068 0.46 2/20
SCHEMBL229040 SCHEMBL229040 0.45 2/20
SCHEMBL3574871 SCHEMBL3574871 0.44 2/20
SCHEMBL2017393 SCHEMBL2017393 0.42 2/20
SCHEMBL319118 SCHEMBL319118 0.42 2/20
SCHEMBL3576485 SCHEMBL3576485 0.41 2/20

Clinical trials — most relevant to MAP2K3 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma PHASE4UNKNOWN
Overcoming Endocrine Resistance in Metastatic Breast Cancer PHASE3UNKNOWN
HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma PHASE1/PHASE2COMPLETED
To Evaluate the Efficacy Beyond Progression of Vemurafenib+Cobimetinib Associated With Local Treatment Compared to Second-line Treatment in Patients With BRAFV600+ Metastatic Melanoma in Focal Progression With First-line+Vemurafenib+Cobimetinib. PHASE2UNKNOWN
Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant PHASE2RECRUITING
MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas PHASE2ACTIVE_NOT_RECRUITING
Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma PHASE2UNKNOWN
A Study to Evaluate RAF265, an Oral Drug Administered to Subjects With Locally Advanced or Metastatic Melanoma PHASE1/PHASE2COMPLETED
MEK162 for Patients With RAS/RAF/MEK Activated Tumors PHASE2COMPLETED
Neoadjuvant Dabrafenib + Trametinib for AJCC Stage IIIB-C BRAF V600 Mutation Positive Melanoma PHASE2ACTIVE_NOT_RECRUITING
Trametinib in Treating Patients With Progressive Metastatic Hormone-Resistant Prostate Cancer PHASE2ACTIVE_NOT_RECRUITING
ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy PHASE2COMPLETED
Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer PHASE2COMPLETED
Cetuximab, Chemotherapy, and Radiation Therapy for Operable Stage III or IV Head and Neck Cancer PHASE2COMPLETED
Clinical Study on the Treatment of Type I Neurofibromatosis With Smeitinib Hydrosulfate Capsule PHASE2NOT_YET_RECRUITING
MEK Inhibitor AZD6244 in Treating Patients With Stage III or Stage IV Melanoma PHASE2COMPLETED
Safety and Efficacy of the Fully Humanized Anti - VEGF Monoclonal Antibody LYN00101 PHASE1WITHDRAWN
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212 PHASE1COMPLETED
Phase I Study of Gemcitabine, Sorafenib and Radiotherapy in Patients With Unresectable Pancreatic Cancer PHASE1COMPLETED
Study of LUT017 Gel to Improve Healing of Skin Wounds After Removal of Benign Lesions in Healthy Adults PHASE1NOT_YET_RECRUITING
Combined MEK, STAT3 and PD-1 Inhibition in Metastatic Pancreatic Ductal Adenocarcinoma PHASE1COMPLETED
LUT017 Gel for Venous Leg Ulcers and Chronic Non-Healing Skin Wounds in Adults PHASE1NOT_YET_RECRUITING
Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer PHASE1COMPLETED
Pathological and Nuclear Medicine Factors for Prognosis in Lung Carcinoma nanCOMPLETED
A Multi-omics Study of BRAF V600E Mutant Colorectal Cancer nanNOT_YET_RECRUITING
BRAF-/MEK-Inhibition With Dabrafenib and Trametinib in Melanoma Patients nanCOMPLETED
Natural History, Pathogenesis and Outcome of Melorheostosis A Rare Osteosclerotic Disease nanRECRUITING
Pertuzumab in First Line Treatment of HER2-positive Metastatic Breast Cancer Patients nanUNKNOWN
Targeted Treatment Plus Tislelizumab and HAIC for Advanced CRCLM Failed From Standard Systemic Treatment nanACTIVE_NOT_RECRUITING
Molecular Phenotype Changes and Personalized Treatment for CRPC nanUNKNOWN

Related proteins — ESM-2 sequence neighbours (a MAP2K3 binder may also engage these)

ProteinNameSimilarity
O09110 — 1.000 O09110 →
Q9DGE0 — 1.000 Q9DGE0 →
Q5E9X2 — 0.998 Q5E9X2 →
MAP2K6 Dual specificity mitogen-activated protein kinase kinase 6 0.997 landscape →
P70236 — 0.996 P70236 →
P47809 — 0.993 P47809 →
MAP2K4 Dual specificity mitogen-activated protein kinase kinase 4 0.990 landscape →
G5EDF7 — 0.990 G5EDF7 →
Q90321 — 0.988 Q90321 →
Q91447 — 0.986 Q91447 →
P31938 — 0.986 P31938 →
Q63980 — 0.985 Q63980 →
Q90891 — 0.985 Q90891 →
MAP2K1 Dual specificity mitogen-activated protein kinase kinase 1 0.985 landscape →
Q05116 — 0.984 Q05116 →
P29678 — 0.983 P29678 →
Q1HG70 — 0.983 Q1HG70 →
MAP2K2 Dual specificity mitogen-activated protein kinase kinase 2 0.983 landscape →
Q9XT09 — 0.983 Q9XT09 →
Q4KSH7 — 0.982 Q4KSH7 →
P36506 — 0.982 P36506 →
Q01986 — 0.982 Q01986 →
Q24324 — 0.981 Q24324 →
Q20347 — 0.981 Q20347 →
P10506 — 0.981 P10506 →
Q5QN75 — 0.981 Q5QN75 →
MAP2K7 Dual specificity mitogen-activated protein kinase kinase 7 0.980 landscape →
Q9WVS7 — 0.980 Q9WVS7 →
Q10664 — 0.980 Q10664 →
Q62862 — 0.978 Q62862 →